Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
59 hedge funds and large institutions have $274M invested in Adaptimmune Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.19% less ownership
Funds ownership: 11.04% → 10.85% (-0.19%)
8% less capital invested
Capital invested by funds: $299M → $274M (-$24.4M)
13% less funds holding
Funds holding: 68 → 59 (-9)
30% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 20
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$2.04M |
| 2 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
+$1.71M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.24M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$950K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$306K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.18M |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$1.24M |
| 3 |
Renaissance Technologies
New York
|
-$1.21M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.13M |
| 5 |
D.E. Shaw & Co
New York
|
-$883K |
ADAP Hedge Fund Activity: Q2 2019 in Review
59 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2019, worth a combined $274M — down 8.2% from $299M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADAP and 3 opened new positions — a net loss of 7 holders — while 20 trimmed existing stakes and 14 added.
The largest buyer was Man Group, adding an estimated $2.04M. The largest seller was Millennium Management, cutting an estimated $5.18M.
- 59 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2019, down from 68 in Q1 2019.
- Funds reported $274M of Adaptimmune Therapeutics stock for Q2 2019, down 8.2% quarter-over-quarter.
- 3 funds opened new Adaptimmune Therapeutics positions in Q2 2019 and 10 closed out, a net change of -7 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2019 was Man Group, an estimated $2.04M added.
- The largest Adaptimmune Therapeutics seller in Q2 2019 was Millennium Management, an estimated $5.18M sold.
Based on aggregated 13F filings for Q2 2019.